NASDAQ: APGE
Apogee Therapeutics Inc Stock

$33.11+1.07 (+3.34%)
Updated Apr 17, 2025
APGE Price
$33.11
Fair Value Price
$2.35
Market Cap
$1.97B
52 Week Low
$26.20
52 Week High
$63.50
P/E
-10.03x
P/B
2.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$182.15M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$171M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

APGE Overview

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine APGE's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
APGE
Ranked
#417 of 463

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important APGE news, forecast changes, insider trades & much more!

APGE News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APGE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APGE ($33.11) is overvalued by 1,306.2% relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
APGE ($33.11) is not significantly undervalued (1,306.2%) relative to our estimate of its Fair Value price of $2.35 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APGE due diligence checks available for Premium users.

Valuation

APGE fair value

Fair Value of APGE stock based on Discounted Cash Flow (DCF)

Price
$33.11
Fair Value
$2.35
Overvalued by
1,306.20%
APGE ($33.11) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APGE ($33.11) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APGE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

APGE price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-10.03x
Industry
-177.72x
Market
27.98x

APGE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.75x
Industry
4.05x
APGE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APGE's financial health

Profit margin

Revenue
$0.0
Net Income
-$67.2M
Profit Margin
0%
APGE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$754.0M
Liabilities
$37.2M
Debt to equity
0.05
APGE's short-term assets ($529.71M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGE's short-term assets ($529.71M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$67.7M
Investing
$46.4M
Financing
$44.4M
APGE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APGE vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
APGEF$1.97B+3.34%-10.03x2.75x
LGNDC$2.02B+0.33%-477.14x2.43x
MIRMC$1.92B+0.90%-21.14x8.49x
FOLDB$2.05B+1.94%-37.94x10.56x
TARSC$1.89B-0.28%-16.04x8.42x

Apogee Therapeutics Stock FAQ

What is Apogee Therapeutics's quote symbol?

(NASDAQ: APGE) Apogee Therapeutics trades on the NASDAQ under the ticker symbol APGE. Apogee Therapeutics stock quotes can also be displayed as NASDAQ: APGE.

If you're new to stock investing, here's how to buy Apogee Therapeutics stock.

What is the 52 week high and low for Apogee Therapeutics (NASDAQ: APGE)?

(NASDAQ: APGE) Apogee Therapeutics's 52-week high was $63.50, and its 52-week low was $26.20. It is currently -47.86% from its 52-week high and 26.37% from its 52-week low.

How much is Apogee Therapeutics stock worth today?

(NASDAQ: APGE) Apogee Therapeutics currently has 59,503,184 outstanding shares. With Apogee Therapeutics stock trading at $33.11 per share, the total value of Apogee Therapeutics stock (market capitalization) is $1.97B.

Apogee Therapeutics stock was originally listed at a price of $21.23 in Jul 14, 2023. If you had invested in Apogee Therapeutics stock at $21.23, your return over the last 1 years would have been 55.96%, for an annualized return of 55.96% (not including any dividends or dividend reinvestments).

How much is Apogee Therapeutics's stock price per share?

(NASDAQ: APGE) Apogee Therapeutics stock price per share is $33.11 today (as of Apr 17, 2025).

What is Apogee Therapeutics's Market Cap?

(NASDAQ: APGE) Apogee Therapeutics's market cap is $1.97B, as of Apr 19, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Apogee Therapeutics's market cap is calculated by multiplying APGE's current stock price of $33.11 by APGE's total outstanding shares of 59,503,184.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.